PMV Pharmaceuticals 计划于 2027 年第一季度提交 rezatapopt NDA

PMV 已完成 PYNNACLE 试验 II 期单药治疗部分中铂类耐药/难治性卵巢癌患者的主要分析入组。公司现计划于 2027 年第一季度提交 rezatapopt 在该适应症的加速批准 NDA。

关键事实

申报时间: 2026年8月14日 12:00
事件: 申请已提交
方向: 中性
公司: PMVPPMV Pharmaceuticals
资产: rezatapopt
来源: SEC 8-K
可信度: 有来源

来源摘录

EX-99.1 2 pmvp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 • Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027 PRINCETON, N.J., August 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule t

SEC 8-K